胶质母细胞瘤免疫治疗：现状概览

Glioblastoma (GB) is an aggressive brain tumor with standard therapies offering limited but measurable survival benefit. Immunotherapy is expanding the treatment landscape for GB. Immune checkpoint inhibitors (ICIs), including nivolumab and pembrolizumab, have shown benefit in several cancers and are being studied in GB, with ongoing efforts to address the tumor's immunosuppressive environment.

Chimeric Antigen Receptor (CAR) T-cell therapies are also being explored, with new approaches designed to overcome antigen variability and improve access across the blood-brain barrier. Cancer vaccines, especially dendritic cell-based platforms like DCVax-L, have shown promising survival outcomes in clinical trials. Advances in biomarker analysis and genomics are supporting more personalized immunotherapy approaches.

In addition, combination strategies involving ICIs, CAR T-cells, vaccines, and oncolytic viruses are being developed to enhance immune response. This review outlines current immunotherapy approaches in GB, focusing on their mechanisms, clinical development, and future directions. Glioblastoma (GB) is an aggressive and common type of brain cancer, with current treatments offering modest survival benefits. Standard treatments like surgery, chemotherapy, and radiation therapy are not enough to stop the tumor from coming back.

Because of this, researchers are exploring new approaches, including immunotherapy, which uses the body s immune system to fight cancer. Immunotherapy has shown success in treating other cancers, but GB presents unique challenges. The tumor creates an environment that weakens the immune response and prevents treatments from working effectively. This review explores different types of immunotherapy being tested for GB: Immune checkpoint inhibitors (ICIs): Drugs like nivolumab and pembrolizumab help the immune system recognize and attack GB cells.

However, clinical trials show only modest improvements in survival. CAR T-cell therapy: This treatment modifies a patient s immune cells to better target the tumor. While promising, barriers like tumor diversity and the brain s natural defenses make it difficult for CAR T-cells to work effectively.

Cancer vaccines: These aim to train the immune system to recognize GB cells as threats, but results have been mixed, with some showing potential for improving survival. Oncolytic viruses: These viruses selectively infect and kill cancer cells while stimulating an immune response. Early trials suggest they may help when combined with other treatments.